Annual report pursuant to Section 13 and 15(d)

Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)

v3.21.2
Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Basic and diluted numerator:    
Net loss attributable to iBio, Inc. stockholders $ (23,207) $ (16,439)
Deemed dividends – down round of Series A Preferred and Series B Preferred   (21,560)
Preferred stock dividends – iBio CMO Preferred Tracking Stock (260) (261)
Net loss available to iBio, Inc. stockholders $ (23,467) $ (38,260)
Basic and diluted denominator:    
Weighted-average common shares outstanding 195,620 62,795
Per share amount $ (0.12) $ (0.61)